InvestorsHub Logo
Followers 29
Posts 9421
Boards Moderated 0
Alias Born 04/30/2006

Re: longterm42 post# 6247

Saturday, 11/04/2006 8:36:55 PM

Saturday, November 04, 2006 8:36:55 PM

Post# of 30387
Longterm: "where does it state that this was the same test as in 04??????"

"In May 2003, a group of Japanese physicians/scientists agreed to test an

improved Histo-Recaf(TM) kit on cancer tissues to determine the kit's ability to accurately detect cancer cells. The Japanese research teams are conducting the tests on a voluntary basis and without charge to Biocurex. Biocurex is supplying the research teams, free of charge, with the chemicals in the Histo-Recaf(TM)

kit which are required for the tests. In April 2004 Biocurex received notice that approximately 83% of the cancer cases stained with the Histo-RECAF (TM) kit

were clearly positive and distinguishable from normal specimens with amicroscope."





Below is a listing of the people involved, both doctors and scientists taken from the abstract. When the initial report came back in April 2004, the results were reported by BOCX. It was an ongoing study that eventually led to a paper published. It is using the histo-Recaf kit, not anything new. I agree that the independent testing was good but Moro had already given the preliminary results years ago. The testing obviously continued with additional results that were not quite as good as the preliminary results. 72% verses 83%.

bDepartment of Medicine and Medical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, and
Department of Hepatology, Shigei Medical Research Hospital,
cOkayama Citizen's Hospital, Okayama;
dBrain Attack Center, Oota Memorial Hospital, Fukuyama, Japan

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.